Literature DB >> 16296790

Novel hydrofluoroalkane suspension formulations for respiratory drug delivery.

Philippe Rogueda1.   

Abstract

Due to the poor solvent properties of hydrofluoroalkanes, suspension is often the only formulation option for respiratory drug delivery. Research in this area has focussed mainly on two main themes over the past 5 years: new design of stabilisers and particle engineering. Among the most important advances, the introduction of secondary particulate systems and the establishment of porous particles as a viable delivery system must be mentioned. Other noteworthy developments include new classes of stabilisers and surface tailoring approaches. Work has been underpinned by new theoretical insights, via the introduction of atomic force microscopy to measure particle interactions, and the development of the surface tension component approach to predict them. Future areas of development include the formulation of nanoparticles and of non-inhalation therapies in non-pressurised hydrofluoroalkanes. All these aspects are reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296790     DOI: 10.1517/17425247.2.4.625

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  8 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 2.  Controlled delivery systems: from pharmaceuticals to cells and genes.

Authors:  Elizabeth Rosado Balmayor; Helena Sepulveda Azevedo; Rui L Reis
Journal:  Pharm Res       Date:  2011-03-19       Impact factor: 4.200

3.  Particle Surface Roughness Improves Colloidal Stability of Pressurized Pharmaceutical Suspensions.

Authors:  Hui Wang; David S Nobes; Reinhard Vehring
Journal:  Pharm Res       Date:  2019-01-30       Impact factor: 4.200

Review 4.  Advances in metered dose inhaler technology: formulation development.

Authors:  Paul B Myrdal; Poonam Sheth; Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

5.  Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Authors:  Sanjay Sethi; Charles Fogarty; Nicola A Hanania; Fernando J Martinez; Stephen Rennard; Michael Fries; Chad Orevillo; Patrick Darken; Earl St Rose; Shannon Strom; Tracy Fischer; Michael Golden; Sarvajna Dwivedi; Colin Reisner
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-17

6.  Influence of suspension stabilisers on the delivery of protein-loaded porous poly (DL-lactide-co-glycolide) (PLGA) microparticles via pressurised metered dose inhaler (pMDI).

Authors:  Elizabeth Cocks; Satyanarayana Somavarapu; Oya Alpar; David Greenleaf
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

7.  Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants.

Authors:  Libo Wu; Balaji Bharatwaj; Jayanth Panyam; Sandro R P da Rocha
Journal:  Pharm Res       Date:  2007-10-17       Impact factor: 4.200

8.  Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers.

Authors:  Josh D Engstrom; Jasmine M Tam; Maria A Miller; Robert O Williams; Keith P Johnston
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.